Junshi Biosciences: The application for the approval of Triplizumab subcutaneous injection has been accepted, covering 12 indications

LightningPacketLoss · 2026-03-10T12:34:55+00:00

Junshi Biosciences announced that its Trastuzumab injection for tumor treatment has received acceptance for 12 indications, becoming the first domestically produced anti-PD-1 monoclonal antibody subcutaneous injection, expected to provide greater convenience for patients.

LightningPacketLoss

2026-03-10 12:34:55

Abstract generation in progress

Janssen Biotech recently announced that the company’s application for the approval of Tecentriq (atezolizumab) for subcutaneous injection for 12 oncology indications has been accepted.

The announcement states that Tecentriq (atezolizumab) for subcutaneous injection is the first domestically developed anti-PD-1 monoclonal antibody in a subcutaneous formulation to enter the listing application stage, potentially providing greater convenience for patients. The 12 indications included in this application are all the indications for Tecentriq that have been approved in mainland China.

(Janssen Biotech Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes